vs
Side-by-side financial comparison of Sphere 3D Corp. (ANY) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $2.7M, roughly 1.7× Sphere 3D Corp.). On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs 3.1%). NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-23.6M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs -37.4%).
Sphere 3D Corp is a global technology company specializing in cloud computing, data management, and virtualization solutions. It delivers enterprise-grade products and services tailored for small to medium-sized businesses, large enterprise clients, and public sector entities, focusing on optimizing IT infrastructure efficiency and cutting operational costs for end users.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
ANY vs NBY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $2.7M | $4.8M |
| Net Profit | — | $-1.2M |
| Gross Margin | — | 65.2% |
| Operating Margin | -372.7% | -37.2% |
| Net Margin | — | -25.5% |
| Revenue YoY | 3.1% | 126.1% |
| Net Profit YoY | — | 70.5% |
| EPS (diluted) | $-6.96 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.7M | — | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | $2.6M | $4.8M | ||
| Q3 24 | $2.4M | $0 | ||
| Q2 24 | $4.7M | $2.4M | ||
| Q1 24 | $6.9M | $2.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $1.7M | — | ||
| Q1 25 | $-8.8M | — | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $104.0K | $-1.2M | ||
| Q2 24 | $2.1M | $-1.6M | ||
| Q1 24 | $-4.5M | $-3.2M |
| Q4 25 | — | — | ||
| Q3 25 | 25.4% | — | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | 22.1% | — | ||
| Q4 24 | — | 65.2% | ||
| Q3 24 | -16.0% | — | ||
| Q2 24 | 15.2% | 66.3% | ||
| Q1 24 | 38.0% | 68.2% |
| Q4 25 | -372.7% | — | ||
| Q3 25 | -153.8% | — | ||
| Q2 25 | -87.0% | — | ||
| Q1 25 | -184.2% | — | ||
| Q4 24 | -328.7% | -37.2% | ||
| Q3 24 | -218.8% | — | ||
| Q2 24 | -122.4% | -67.4% | ||
| Q1 24 | -26.9% | -87.1% |
| Q4 25 | — | — | ||
| Q3 25 | -162.0% | — | ||
| Q2 25 | 55.2% | — | ||
| Q1 25 | -311.9% | — | ||
| Q4 24 | — | -25.5% | ||
| Q3 24 | 4.4% | — | ||
| Q2 24 | 45.5% | -66.0% | ||
| Q1 24 | -64.5% | -122.2% |
| Q4 25 | $-6.96 | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | $0.06 | — | ||
| Q1 25 | $-0.32 | — | ||
| Q4 24 | $-4.62 | — | ||
| Q3 24 | $0.01 | $-1.92 | ||
| Q2 24 | $0.10 | $-1.37 | ||
| Q1 24 | $-0.27 | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.7M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.3M | $-129.0K |
| Total Assets | $25.1M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | — | ||
| Q3 25 | $5.3M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | $5.4M | $430.0K | ||
| Q3 24 | $5.0M | $776.0K | ||
| Q2 24 | $4.3M | $751.0K | ||
| Q1 24 | $9.3M | $1.8M |
| Q4 25 | $23.3M | — | ||
| Q3 25 | $29.5M | — | ||
| Q2 25 | $32.7M | — | ||
| Q1 25 | $30.7M | — | ||
| Q4 24 | $39.3M | $-129.0K | ||
| Q3 24 | $35.8M | $1.1M | ||
| Q2 24 | $33.4M | $-617.0K | ||
| Q1 24 | $27.5M | $160.0K |
| Q4 25 | $25.1M | — | ||
| Q3 25 | $31.1M | — | ||
| Q2 25 | $34.4M | — | ||
| Q1 25 | $34.3M | — | ||
| Q4 24 | $43.2M | $3.4M | ||
| Q3 24 | $44.3M | $3.9M | ||
| Q2 24 | $44.0M | $3.9M | ||
| Q1 24 | $42.0M | $5.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.1M | $-1.7M |
| Free Cash FlowOCF − Capex | $-23.6M | $-1.7M |
| FCF MarginFCF / Revenue | -867.3% | -35.4% |
| Capex IntensityCapex / Revenue | 275.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-40.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.1M | — | ||
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-5.8M | — | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | $-4.6M | $-1.7M | ||
| Q3 24 | $290.0K | $-2.4M | ||
| Q2 24 | $-3.3M | $-1.4M | ||
| Q1 24 | $-58.0K | $-2.0M |
| Q4 25 | $-23.6M | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $-6.0M | — | ||
| Q1 25 | $-5.1M | — | ||
| Q4 24 | $-13.5M | $-1.7M | ||
| Q3 24 | $-4.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | -867.3% | — | ||
| Q3 25 | -218.7% | — | ||
| Q2 25 | -200.5% | — | ||
| Q1 25 | -181.2% | — | ||
| Q4 24 | -511.9% | -35.4% | ||
| Q3 24 | -184.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -75.3% |
| Q4 25 | 275.4% | — | ||
| Q3 25 | 86.5% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 36.4% | — | ||
| Q4 24 | 338.7% | 0.1% | ||
| Q3 24 | 196.7% | — | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.51× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.79× | — | ||
| Q2 24 | -1.55× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANY
Segment breakdown not available.
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
